Premium
Determination of 1‐(2‐chloroethyl)‐3‐(2,6‐dioxo‐3‐piperidyl)‐1‐nitrosourea in plasma by negative chemical ionization mass spectrometry
Author(s) -
Smith Ronald G.,
Cheung Lily K.,
Feun Lynn G.,
Loo Ti Li
Publication year - 1983
Publication title -
biomedical mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 0306-042X
DOI - 10.1002/bms.1200100704
Subject(s) - chemistry , mass spectrometry , chromatography , chemical ionization , analytical chemistry (journal) , plasma , detection limit , ionization , ion , extraction (chemistry) , organic chemistry , physics , quantum mechanics
A sensitive and specific method for the quantitative determination of a new antitumor agent,l‐(2‐chloroethyl)‐3‐(2,6‐dioxo‐3‐piperidyl)‐1‐nitrosourea, (PCNU) has been developed for the analysis of plasma. This assay involves extraction of the plasma sample, separation of the drug by thin‐layer chromatography and mass spectrometric detection of the negative ions derived from the unchanged drug and its 2 H 4 ‐labeled analog. Ion current profile peaks are obtained when drug samples are introduced into the heated source using a desorption chemical ionization probe. Detection limits are below 1.0 ng ml −1 of plasma. This method has been applied to determine the in vitro rate of decomposition of PCNU in plasma and the plasma clearance of this drug from a cancer patient.